Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | -1.67% | 137.43 | 0.7% | $2196.88m | |
| PFE | Pfizer Inc. | -2.81% | 33.60 | 0.9% | $1393.77m | |
| MRK | Merck & Co., Inc. | -2.23% | 78.52 | 0.7% | $1292.94m | |
| ABBV | AbbVie, Inc. | -0.59% | 75.28 | 2.3% | $1206.98m | |
| BMY | Bristol-Myers Squibb Co. | -1.71% | 56.88 | 1.0% | $1137.67m | |
| LLY | Eli Lilly & Co. | 0.16% | 141.84 | 1.1% | $861.43m | |
| NVS | Novartis AG | -2.18% | 83.86 | 0.2% | $293.22m | |
| AZN | AstraZeneca Plc | -2.71% | 43.11 | 1.2% | $291.10m | |
| GSK | GlaxoSmithKline Plc | -0.90% | 37.57 | 0.2% | $251.33m | |
| SNY | Sanofi | -3.30% | 44.60 | 0.2% | $169.62m | |
| NVO | Novo Nordisk A/S | -3.46% | 58.56 | 0.1% | $168.58m | |
| FTSV | Forty Seven, Inc. | 0.05% | 95.51 | 0.0% | $145.52m | |
| BHC | Bausch Health Cos., Inc. | 1.51% | 14.84 | 0.0% | $99.58m | |
| RGEN | Repligen Corp. | -4.03% | 96.65 | 7.1% | $69.48m | |
| RETA | Reata Pharmaceuticals, Inc. | -2.63% | 134.65 | 3.4% | $63.83m |
Company Profile
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.